Fig. 3.

Enavatuzumab inhibited the growth of primary tumors and metastases in xenograft models of breast cancer. Established MCF7 (a) and HCC70 (b) tumors were treated with enavatuzumab or a human IgG1 control antibody at 10 mg/kg three times per week, with 10 animals in each dosing group. Tumor volumes were measured on each dosing day; points, mean; bars, SEM. Differences in tumor volumes between the enavatuzumab and control treated groups were significant (p < 0.001) in both models. c–e Established MB231 variant tumors were treated with enavatuzumab or a human IgG1 control antibody thrice per week, with 7 mice in each dosing group. c Tumor volumes were measured on each dosing day; points, mean; bars, SEM. d Metastases were quantified in lungs harvested on day 37; both micrometastases (<4 cells) and metastatic clusters >4 cells were enumerated. Enavatuzumab treatment significantly inhibited the growth of primary tumors and micrometastases at 10, 3, and 1 mg/kg and inhibited the development of larger metastases at 10 and 3 mg/kg (*p < 0.05; **p < 0.001). e Immunohistochemical staining of human cytokeratin-positive metastases in mouse lungs